Tempero Bio, Inc., a clinical-stage biopharmaceutical company developing transformative treatments for substance use disorders, today announced the closing of a $70 million Series B financing. The ...

An international research team has conceived a dual-component controller for three-phase inverters that can reportedly ...

McGill researchers found lecanemab may be less effective in women, prompting calls for more personalized treatment and ...

The company, launched with help from ex-Novartis executives, is targeting glutamate signaling in the brain to help treat ...

"We are excited to initiate the Phase 3 study and we believe that Piclidenoson's oral dosage and excellent safety record, ...

A significant benefit was observed with Tysabri over Rebif in delaying SPMS disability progression when therapeutic lag was ...

WACC (Weighted Average Cost of Capital): 11.05%, coming from 11.5% cost of equity (about 11% I use for a no-moat stock, but I ...

Scientists have developed a revolutionary AI "fingerprint" technology that can accurately show how cancer cells respond to ...

Augustine Therapeutics has raised €78m ($85m) in funding to support the development of its lead candidate as it enters a ...

Duke University blood cancer specialist Lindsay Rein, MD, has developed a rare expertise in myeloproliferative neoplasms ...

On this World TB Day, the emergence of the M72 vaccine shines a much-needed light of hope in our battle against tuberculosis, ...

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...